Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

34.95 USD UNCHANGED
Streaming Delayed Price Updated: 5:33 PM EDT, Apr 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Bioxcel Therapeutics Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags GENE OMED ONTX
From Benzinga
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags MRNS MESO Offerings
From Benzinga
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (IND) application for lead... 
From GlobeNewswire News Releases
Sum Up The Parts: IWC Could Be Worth $135
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags News PRNB MRK
From Benzinga
The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags NURO BIOC MRK
From Benzinga
The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs ... 
Tags CPRX Top Stories IPCI
From Benzinga
Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Transcat, Inc.... 
From GlobeNewswire News Releases
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags Market News MGNX WMGI
From Benzinga
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
24 Stocks Moving In Monday's Pre-Market Session
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) rose 9.6 percent to $8.12 in pre-market trading. Ceragon Networks Ltd (NASDAQ: CRNT) ... 
Tags News Losers Benzinga
From Benzinga
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (“IND”) application for its... 
From GlobeNewswire News Releases
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
Analysts Forecast 33% Upside For IWC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags Benzinga PFE NBRV
From Benzinga
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit ... 
Tags BLUE ADXS BLCM
From Benzinga
BioXcel Therapeutics to Present at the 2018 BIO Investor Forum
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags MRK CYTR ASMB
From Benzinga
BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
First-in-human Phase 1b / 2 combination trial to treat rare form of prostate cancer, tNEPC, using BXCL701 and a PD-1 checkpoint inhibitor 
From GlobeNewswire News Releases
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
Clinical partnership to develop triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and a checkpoint inhibitor 
From GlobeNewswire News Releases
BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs
Strategic hire completes recruitment of world class leadership team with broad pharmaceutical expertise 
From GlobeNewswire News Releases
The Week Ahead: Mr. Dorsey Goes To Washington, Employment And Wage Data On Tap
Below is a list of notable corporate events for the week beginning September 3. Note, this list is not comprehensive and all dates are ... 
Tags Trading Ideas OPRA OLLI
From Benzinga
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
Support preparation and implementation of proof of concept and registration trials for two lead clinical program 
From GlobeNewswire News Releases
BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development
Appoints world renowned immuno-oncology clinicians and scientists 
From GlobeNewswire News Releases
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines... 
From GlobeNewswire News Releases
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.